| abstract |
The invention relates to a variant nisin peptide, wherein the variant nisin peptide is a modified variant of wild-type nisin, wherein the modification comprises or consists of an amino acid residue modification selected from: i) M17Q or M17A; ii) T2L; and iii) one set of modified hinge residues selected from a) N20H and M21T, b) N20V, M21G, and K22A, c) N20V, M21G, and K22V or d) N20V, M21G, and K22T; or v) combinations of modifications i), ii), and iii), and related medical uses and products comprising such nisin peptides. |